<DOC>
	<DOCNO>NCT01715909</DOCNO>
	<brief_summary>This open-label , randomize , adaptive , 2-arm , multicenter study evaluate pharmacokinetics pharmacodynamics oseltamivir ( Tamiflu ) immunocompromised child , less ( &lt; ) 13 year age , confirm influenza infection . Participants randomize receive either standard dose triple dose oseltamivir orally daily minimum 5 day 20 day . Infants &lt; 1 year age randomize standard dose arm .</brief_summary>
	<brief_title>A Pharmacokinetic/Pharmacodynamic Study Oseltamivir Immunocompromised Children With Confirmed Influenza Infection</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>Male female child , &lt; 13 year age Rapid influenza diagnostic test ( RIDT ) , polymerase chain reaction ( PCR ) , viral culture positive influenza Immunocompromised Symptoms/signs suggestive influenza like illness ( ILI ) Less equal ( &lt; /= ) 96 hour onset ILI first dose study drug Clinical evidence severe hepatic impairment Infants &lt; 2 week age , born preterm , postmenstrual age ( PMA ) &lt; 36 week Clinical evidence significant renal impairment Allergy oseltamivir excipients Hereditary fructose intolerance Received antiviral treatment activity influenza ( example amantadine , rimantadine , oseltamivir , laninamivir , peramivir , zanamivir , ribavirin ) probenecid medication within 2 week prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>